Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Infections, Meningococcal Clinical Trial

Official title:

Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00471081
• Other study ID #: 109375
• Status: Completed
• Phase: Phase 2
• Start date: July 5, 2007
• Est. completion date: November 26, 2008

Study information

• Verified date: June 2019
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.

Description:

The protocol posting has been amended to reflect changes as a consequence of an amendment to the protocol and also to comply with the FDA amendment Act, Sep 2007. Sections impacted are Brief Title, Official Title of the study, Brief Summary, Key Inclusion & Exclusion criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 385
• Est. completion date: November 26, 2008
• Est. primary completion date: October 23, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Months to 9 Months

Eligibility

Inclusion Criteria:

• Subjects whose parents/guardians the investigator believes can and will comply with the requirements of the protocol

• A male or female of 9 months of age (has not attained 10 months of age) at the time of enrollment.

• Up to date on vaccinations based on ACIP recommendations and the standard practice at the investigational site.

• Written informed consent obtained from parents/guardian of the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding enrollment, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.

• Planned administration/ administration of a vaccine not foreseen by the study protocol within 1 month of a dose of study vaccine(s), with the exception of influenza vaccine.

• Planned administration of a tetanus toxoid (TT) containing vaccine throughout the active phase of the study (through one month after the last vaccination).

• Previous vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, C W and/or Y.

• History of meningococcal diseases.

• Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing is required).

• A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.

• History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.

• Major congenital defects or serious chronic illness.

• History of any neurologic disorders or seizures.

• Acute disease at the time of enrollment.

• Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the active phase of the study (through one month after the last dose of study vaccine).

Related Conditions & MeSH terms

• Infections, Meningococcal
• Meningococcal Infections

Intervention

Biological:
• Meningococcal vaccine GSK134612
One or 2 intramuscular injections.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Amarillo	Texas
United States	GSK Investigational Site	Antioch	California
United States	GSK Investigational Site	Benton	Arkansas
United States	GSK Investigational Site	Birmingham	Alabama
United States	GSK Investigational Site	Birmingham	Georgia
United States	GSK Investigational Site	Canton	Ohio
United States	GSK Investigational Site	Erie	Pennsylvania
United States	GSK Investigational Site	Fremont	California
United States	GSK Investigational Site	Greenville	Pennsylvania
United States	GSK Investigational Site	Hayward	California
United States	GSK Investigational Site	Lakewood	Colorado
United States	GSK Investigational Site	Little Rock	Arkansas
United States	GSK Investigational Site	Littleton	Colorado
United States	GSK Investigational Site	Littleton	Colorado
United States	GSK Investigational Site	Madera	California
United States	GSK Investigational Site	Santa Rosa	California
United States	GSK Investigational Site	Vacaville	California
United States	GSK Investigational Site	Westminster	Colorado
United States	GSK Investigational Site	Wheat Ridge	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

References & Publications (2)

Klein N et al. Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Toddlers: 1-year Persistence. Abstract presented at the 51st Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Chicago, US, 17-20 September 2011.

Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013 Jul;32(7):760-7. doi: 10.1097/INF.0b013e31828693c5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y) Antibody Titers Greater Than or Equal to the Cut-off Value	The cut-off value for the hSBA titers was greater than or equal to (=) 1:8.	One month after the last dose (at Month 4)
Secondary	Number of Subjects With Serum Bactericidal Assay Using hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers Greater Than or Equal to the Cut-off Value	The cut-off value for the hSBA titers was greater than or equal to (=) 1:8.	One month after the first dose (at Month 1)
Secondary	Number of Subjects With Serum Bactericidal Assay Using hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers Greater Than or Equal to the Cut-off Value	The cut-off value for the hSBA titers was greater than or equal to (=) 1:4.	At Month 1 (for GSK 134612 2 doses Group only) and Month 4
Secondary	hSBA-MenA, hSBA-MenC, hSBA-MenW -135 and hSBA-Men-Y Antibody Titers	Antibody titers were presented as geometric mean titers (GMTs).	At Month 1 (for GSK 134612 2 doses Group only) and Month 4
Secondary	Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers Greater Than or Equal to the Cut-off Value	The cut-off value for the rSBA titers was greater than or equal to (=) 1:8.	At Month 1 (for GSK 134612 2 doses Group only) and Month 4
Secondary	Number of Subjects With Serum Bactericidal Assay Using rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Greater Than or Equal to the Cut-off Value	The cut-off value for the rSBA titers was greater than or equal to (=) 1:128.	At Month 1 (GSK 134612 2 doses Group only) and Month 4
Secondary	rSBA-MenA, rSBA-MenC, rSBA-MenW -135 and rSBA-Men-Y Antibody Titers	Antibody titers were presented as geometric mean titers (GMTs).	At Month 1 (GSK 134612 2 doses Group only) and Month 4
Secondary	Number of Subjects With Anti-polysaccharide Meningococcal Serogroup A (Anti-PSA), Serogroup C (Anti-PSC), Serogroup W-135 (Anti-PSW-135) and Serogroup Y (Anti-PSY) Antibody Concentrations Greater Than or Equal to the Cut-off Value	The cut-off value for the anti-polysaccharide concentrations was greater than or equal to (=) 0.3 micrograms per milliliter (µg/mL).	At Month 1 (GSK 134612 2 doses Group only) and Month 4
Secondary	Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations Greater Than or Equal to the Cut-off Value	The cut-off value for the anti-polysaccharide concentrations was greater than or equal to (=) 2.0 micrograms per milliliter (µg/mL).	At Month 1 (GSK 134612 s doses Group only) and Month 4
Secondary	Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations	Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL).	At Month 1 (GSK 134612 2 doses Group only) and Month 4
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.	During the 4-day (Days 0-3) and 8-day (Days 0-7) periods following each vaccination
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Assessed solicited general symptoms were drowsiness, fever [defined as axillary, oral, tympanic or rectal temperature equal to or above (=) 38 degrees Celsius (°C)], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever higher than (>) 40.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 4-day (Days 0-3) and 8-day (Days 0-7) periods following each vaccination
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	Up to 1 month post-vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Up to study end (Month 9)
Secondary	Number of Subjects With New Onset Chronic Ilnesses (NOCI)	NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.	Up to study end (Month 9)
Secondary	Number of Subjects Reporting Rash	Rash assessed included hives, idiopathic thrombocytopenic purpura and petechiae.	Up to study end (Month 9)
Secondary	Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits	Among AEs prompting emergency room visits were: infections, injuries, skin diseases and respiratory diseases.	Up to study end (Month 9)

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.